MK-3475 in Combination With Standard RCHOP Therapy for Previously Untreated Diffuse Large B-cell Lymphoma

Trial Profile

MK-3475 in Combination With Standard RCHOP Therapy for Previously Untreated Diffuse Large B-cell Lymphoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Dec 2017

At a glance

  • Drugs Pembrolizumab (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Rituximab; Vincristine
  • Indications Diffuse large B cell lymphoma; Follicular lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 12 Dec 2017 Preliminary results (n=17) presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
    • 24 Oct 2017 Planned number of patients changed from 20 to 30.
    • 24 Oct 2017 Planned End Date changed from 1 Nov 2020 to 24 Nov 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top